Skip to main content
. 2020 Jan 3;20:1. doi: 10.1186/s12935-019-1086-5

Table 2.

Successfully established primary glioma PDXs from November 2016 to May 2018

WHO grades WHO classification Cases of established PDXs PDXs success rate Latency time (weeks, median range)
II Diffuse astrocytoma, IDHWT 1 1/3 11
III Anaplastic OGDs, IDHMUT-1p/19qcodeleted 1 60.00% (3/5) 18 (14–22)
Anaplastic OGDs, NOS 2
IV GBM, IDHWT 7 87.50% (7/8) 9 (5–22)
Total 11 68.75% (11/16) 13 (5–22)

IDH, isocitrate dehydrogenase; WT, wildtype; MUT, mutant; OGD, oligodendroglioma; GBM, Glioblastoma; PDX, patient-derived xenograft